The consensus forecast among Wall Street equity analysts tracking RCEL on the NASDAQ lists the stock with a Strong Buy recommendation, accompanied by an average twelve-month price target ranging between $10.20 and $11.14 per share. Forecast models project continued double-digit annual revenue growth and narrowing net losses as the company expands its product adoption across international medical markets.